Columbia University Medical Center and New York-Presbyterian, in coordination with the Foundation for the National Institutes of Health Biomarkers Consortium, is launching a three-year research collaboration to develop new methods for analyzing digital images that track a patient’s response to cancer therapy.
As the debate around Galleri, the multi-cancer detection test developed by GRAIL Inc., rages on, fueled most recently by the full-steam-ahead support it has received from regulatory and legislative bodies, NCI Director Anthony Letai has turned his attention to the available data.
